Drugs / SARS-CoV-2 rS antigen/Matrix-M Adjuvant
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05875701 | Mar → Nov 2023 | COVID-19 | Novavax | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 rS antigen/Matrix-M Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05875701 ↗ |
| Route | Intramuscular | “1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1” NCT05875701 ↗ |